The ADAURA study included patients with common EGFR mutations who could receive adjuvant chemotherapy before osimertinib therapy, showing that osimertinib, compared to placebo, brought a highly significant reduction in the risk of disease recurrence in all studied subgroups [ 15 ].
← all excerpts
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the <i>EGFR</i> Gene.
1
—
—